Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Elicio Therapeutics ( (ELTX) ) has issued an announcement.
On January 23, 2025, Elicio Therapeutics announced the addition of a corporate presentation on its website, detailing updates on its clinical programs and projected plans. The presentation highlighted ELI-002’s progress, including its potential as a monotherapy for high relapse-risk mKRAS+ cancers, and reported significant T-cell response results from Phase 1 trials. The company also raised $33 million to support its operations into Q2 2025, with several clinical trials planned in the coming years, positioning Elicio to advance its pipeline and reinforce its place in the cancer immunotherapy market.
More about Elicio Therapeutics
Elicio Therapeutics is a clinical-stage biotechnology company focused on developing innovative lymph node-targeted cancer immunotherapies. The company utilizes its proprietary Amphiphile (AMP) technology to deliver payloads to lymph nodes, enhancing immune responses to combat cancer. Elicio’s primary product candidate, ELI-002, is an off-the-shelf cancer vaccine targeting common KRAS mutations responsible for a significant portion of solid tumors, particularly in pancreatic and colorectal cancers.
YTD Price Performance: 25.49%
Average Trading Volume: 26,605
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $69.6M
Learn more about ELTX stock on TipRanks’ Stock Analysis page.
